Transgene to start clinical development of lead myvac individualized immunotherapy, TG4050, in 2019, under its partnership with NEC

0
28

Transgene to start clinical development of lead myvac individualized immunotherapy, TG4050, in 2019, under its partnership with NEC

LEAVE A REPLY

Please enter your comment!
Please enter your name here